ArticleJNCI cancer spectrum2026
Dietary intake of one-carbon nutrients and colorectal cancer risk according to TP53 status.
Article in JNCI cancer spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Thriving after cancer: a summary of the special collection on the benefits of exercise and nutrition in cancer survivorship.JNCI cancer spectrum · 2026Article
- Cytotoxic T-cell exhaustion analyses by in situ single-cell immunofluorescence in relation to colorectal cancer patient age, tissue bacteria and mortality.BMJ oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundAccumulating evidence suggests that one-carbon nutrient intake reduces the risk of colorectal cancer (CRC), although folate fortification has been associated with a temporary increase in CRC incidence. We hypothesized that one-carbon nutrients might harbor preventive and protumor effects on CRC according to tumor conditions and investigated whether the effect of one-carbon nutrients on CRC risk differs by TP53 status.
methodsIn this prospective study of 21 708 Japanese participants, we applied a multivariable Cox proportional hazards model and examined the associations of dietary intakes of folate, vitamin B6, vitamin B12, and methionine with TP53-overexpressing (n = 192), TP53-nonoverexpressing (n = 301), TP53-mutated (n = 180), and TP53 wild-type (n = 134) CRC risk defined by TP53 immunohistochemistry and target sequence.
resultsVitamin B12 and methionine intakes were not associated with any CRC subtypes defined by TP53 status. Meanwhile, folate intake was marginally associated with decreased TP53-mutated CRC risk (hazard ratio [HR] with 95% confidence interval [CI] for the highest folate intake quartile compared with the lowest (HR = 0.82, 95% CI = 0.46 to 1.45) and increased TP53 wild-type CRC risk (HR = 1.50, 95% CI = 0.78 to 2.90). A heterogeneous effect of folate on CRC subtypes was detected (P = .03 for heterogeneity between TP53 mutation statuses). In women, the association between vitamin B6 and CRC also differed by TP53 mutation status (P = .007 for heterogeneity). The hazard ratio of vitamin B6 was 0.71 (95% CI = 0.30 to 1.67) for TP53-mutated CRC and 3.89 (95% CI = 1.79 to 8.49) for TP53 wild-type CRC. However, no heterogeneous effects were observed between TP53 expression statuses.
conclusionThis study supports the hypothesis that the effect of one-carbon nutrient intake on CRC differs according to tumor conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.